Haleon plc (LON:HLN – Get Free Report) has received an average recommendation of “Hold” from the six brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is GBX 399.
HLN has been the topic of several research analyst reports. Royal Bank Of Canada lifted their price objective on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft raised their target price on Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a research report on Friday, July 31st. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 400 price target on shares of Haleon in a research note on Friday, July 31st. Berenberg Bank boosted their price target on Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. reduced their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research note on Thursday, June 25th.
Get Our Latest Research Report on Haleon
Haleon Stock Performance
Haleon (LON:HLN – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, research analysts forecast that Haleon will post 19.5033282 earnings per share for the current fiscal year.
About Haleon
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Recommended Stories
- Five stocks we like better than Haleon
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
